UPDATE: Jefferies Raises Target on Insulet to $24

Jefferies maintains its Buy rating on Insulet PODD and raises its price target to $24 from $21 a share as the company's next generation of pods awaits FDA approval. Jefferies says, "Insulet closed out 2011 with 4Q sales of $47.2mn, largely in-line with expectations. The company remains in active communication with the FDA on the next gen pod, with approval expected by the end of 1Q/early 2Q. The launch of the next gen pod is anticipated at ADA in June and will have a positive impact on both revenue growth and profitability." PODD closed at $19.88 a share yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!